Current characteristics and outcome of cytomegalovirus infections after kidney transplantation

Transplant Infectious Disease

Volumn 16, Issue 4, 2014, Pages 568-577

  Helantera I ^a,b   Schachtner, T ^a   Hinrichs, C ^a   Salmela, K ^b   Kyllonen L ^b   Koskinen, P ^b   Lautenschlager, I ^b   Reinke, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CMV disease; Cytomegalovirus; Kidney transplantation; Outcome

Indexed keywords

ANTIVIRUS AGENT; BACTERIAL PROTEIN; CHAPERONE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; VALGANCICLOVIR; VIRE1 PROTEIN, AGROBACTERIUM TUMEFACIENS;

ADULT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FINLAND; GERMANY; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FINLAND; GANCICLOVIR; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; RETROSPECTIVE STUDIES;

EID: 84905585111     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12247     Document Type: Article

References (23)

1. Helanterä I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH. Viral impact on long-term kidney graft function. Infect Dis Clin N Am 2010; 24 (2): 339-371.
2. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (2): 262-274.
3. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
4. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2013; 96 (4): 333-360.
5. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (S4): S78-S86.
6. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70 (8): 1166-1174.
7. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90 (12): 1427-1431.
8. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 (9): 2106-2113.
9. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10 (1): 157-161.
10. Helanterä I, Kyllönen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 2010; 10 (9): 2026-2032.
11. Helanterä I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int 2011; 24 (12): 1170-1178.
12. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55 (2): 713-723.
13. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3 (6): 708-714.
14. Piiparinen H, Höckerstedt K, Grönhagen-Riska C, Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30 (33): 258-266.
15. Asadullah K, Prösch S, Audring H, et al. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 1999; 141 (1): 94-102.
16. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49 (12): 1373-1379.
17. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181 (2): 717-720.
18. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67 (1): 94-97.
19. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 (6): 829-833.
20. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5): 1205-1213.
21. Muheim C, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002; 74 (2): 226-236.
22. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant patients. Am J Transplant 2013; 13 (9): 2402-2410.
23. Freyer JF, Heath AB, Anderson R, Minor PD and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays. WHO ECBS Report 2010; WHO/BS/10.2138.